Remypure is Beneo’s first high-performance rice starch that qualifies for clean-label status worldwide, the company says.
Photo © iStockphoto.com/Alasdair Thomson
Beneo (Morris Plains, NJ) has launched a new rice starch that is natural, clean-label, and stable under harsh processing conditions such as low pH, high temperature, or high shear.
Remypure is Beneo’s first high-performance rice starch that qualifies for clean-label status worldwide, the company says. The firm says the starch's performance is on par with that of non-clean-label starches. “Due to Remypure’s new thermal production process, which is entirely natural, Beneo’s functional native rice starch achieves performance levels comparable to chemically modified food starches without using any chemicals,” the press release states.
Remypure is suited for products like sauces, jarred baby food, dairy desserts, and fruit preparations. It has a clean taste and can improve the shelf-life stability and texture of products and can be supplied in different varieties depending on the application, ranging from creamy to soft.
“As a result of this new product development from Beneo, food manufacturers now have a versatile, clean-label rice starch available, allowing viscosity buildup suitable for both gentle and demanding processing conditions,” the company says.
Also read:
Clean-Label Options for Gums and Hydrocolloids
Clean Label: Everyone’s Doing It
Different Paths to Clean-Label Cocoa
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.